
French doctor labelled ‘atomic bomb of paedophilia' jailed for 20 years for child sex abuse
Joel Le Scouarnec was handed a 20-year jail sentence for sexual abuse.
He admitted to abusing hundreds of patients, most of them children.
Some victims were disappointed with the sentence.
A French court on Wednesday gave the maximum 20-year jail term to a surgeon who admitted sexually abusing hundreds of patients, most of them children, but victims, some in tears, expressed disappointment with the verdict.
The three-month trial of Joel Le Scouarnec, 74, has brought to light the extent of his crimes and the suffering of his victims but also raised questions about why more was not done sooner to stop him.
Le Scouarnec, one of the most prolific convicted sex predators in France's history, was already in prison after being sentenced in 2020 to 15 years for raping and sexually assaulting four children, including two of his nieces.
The 20-year sentence handed down by presiding judge Aude Buresi was the maximum that could be given on the charge of aggravated rape in France, where sentences are not added together on individual counts.
Le Scouarnec will not be able to ask for parole until two-thirds of his sentence is served.
But the court in Vannes in the western region of Brittany rejected a rare demand from prosecutors that he should be held in a centre for treatment and supervision even after any release.
The court cited his age and his 'desire to make amends'.
Wearing a black jacket, Le Scouarnec listened to the verdict without flinching.
Damien Meyer/AFP
Cries of 'shame on the justice system' rang out in a separate room where victims watched the proceedings on a video screen, according to two sources.
'What a disappointment!' one of the victims, Manon Lemoine, said outside the courthouse, fighting back tears.
Some of the survivors of the retired surgeon's abuse shared a tearful embrace.
Another victim, Amelie Leveque, said she felt 'humiliated by this verdict'.
Child rights advocates say the case highlights systemic failures that allowed Le Scouarnec to repeatedly commit sexual crimes.
Le Scouarnec was also banned from contact with minors and practising medicine.
He will not appeal his conviction, said his lawyer Maxime Tessier.
The prosecutor has said that in the US, Le Scouarnec could have been jailed for '2 000 years'.
In the trial, which began in February, Le Scouarnec admitted sexually assaulting or raping 299 patients - 256 of them under 15 - in hospitals between 1989 and 2014, many while they were under anaesthesia or waking up after operations.
Survivors of the surgeon's abuse staged a protest outside the court holding signs such as 'Never again' and 'I accuse you'.
They also held signs representing 355 victims.
That number included 'forgotten victims and those whose cases have been dismissed', said Lemoine.
Another victim, Celine Mahuteau, sent a letter to President Emmanuel Macron saying France has not implemented a national policy 'to prevent paedophilia'.
'I am not asking the court for leniency,' Le Scouarnec said on Monday.
'Simply grant me the right to become a better person.'
The surgeon also said he considered himself 'responsible' for the death of two of his victims - Mathis Vinet, who died after an overdose in 2021 in what his family says was suicide, and another man who was found dead in 2020.
Le Scouarnec documented his crimes, noting his victims' names, ages, addresses and the nature of the abuse.
In his notes, the doctor described himself as a 'major pervert' and a 'paedophile'.
'And I am very happy about it,' he recorded.
In 2005, he received a four-month suspended prison sentence after investigators linked his credit card to the online purchase of child sexual abuse material.
But Le Scouarnec was neither required to undergo treatment nor barred from practising medicine.
While Le Scouarnec has asked his victims for forgiveness, many have questioned the sincerity of his apologies, which he repeated almost mechanically.
'You are the worst mass paedophile who ever lived,' said one of the lawyers representing the victims, Thomas Delaby, describing Le Scouarnec as an 'atomic bomb of paedophilia'.
There has been frustration among some that the trial has not had the impact in France they hoped for.
The case has not won the attention given to the case of Dominique Pelicot, who was jailed last year for recruiting dozens of strangers to rape his now ex-wife Gisele.
Health Minister Yannick Neuder said he would work with Justice Minister Gerald Darmanin to ensure that 'never again will we find ourselves in a situation where patients and vulnerable children' are exposed to predators.
Gabriel Trouve, one of the victims, said many were relieved and looked forward to resuming their lives.
'We can, I think, be proud of this fight we didn't choose, but have decided to take on nonetheless,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Four wounded, one killed in southern Virginia shooting
June 2 (UPI) -- Five people were shot, including one person fatally, in a shooting that erupted at a large outdoor gathering in southern Virginia over the weekend, authorities said. According to preliminary information, the early Sunday shooting involved gunmen in a Chrysler sedan and individuals at a party in the 100 block of Carver Drive in Danville, a city of about 42,000 near the Virginia-North Carolina border. The Danville Police Department said in a statement that the shooting occurred shortly before 1:30 a.m. local time Sunday. Officers dispatched to the area following reports of shots fired found a deceased man, later identified as Jay'Shaun Tiejae White, 22, in the front passenger seat of a Chrysler sedan with gunshot wounds to his upper body. Officers found the suspected driver of the vehicle, identified as a 26-year-old man, suffering from a gunshot wound on an adjacent street. The victim was then transported by ambulance to Sovah Health Danville. Three additional victims later arrived on their own at the health center with injuries from the gunfight, the police department said. The victims have been identified as two men, ages 31 and 25, and a 19-year-old woman. The woman has since been treated and released, while the three men have been transferred to other medical facilities, police said. Juwan Montel Baker, 26, of Danville, has been arrested in connection with the shooting. Police said he was a passenger in the sedan, and he has been charged with three counts each of discharging a firearm from a moving vehicle, malicious wounding and use of a firearm in the commission of a felony. According to The Gun Violence Archive, there have been at least 127 mass shootings involving four or more people shot so far in the United States this year.


CBS News
an hour ago
- CBS News
11 stabbed at Salem, Oregon mission that aids homeless people
Eleven people were stabbed Sunday evening at a Salem, Oregon mission that aids homeless people and a male suspect was in custody, police said. All the victims were brought to a local hospital with "varying types of injuries," police added. It happened at the Union Gospel Mission, which helps "men, women, and children break free from homelessness through the transforming grace of Jesus Christ," according to its website. There was no word on what prompted the attack or the suspect's identity.
Yahoo
an hour ago
- Yahoo
Ipsen S.A. - Initiation of the share buy-back program
Regulated information Ipsen initiates a share buy-back program to cover its free employee share-allocation plan PARIS, FRANCE, 2 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 600,000, or about 0.72% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen's free employee share-allocation plan. This program is made pursuant to the authorization granted by the Company's Annual General Meeting, held on 21 May 2025. ENDS About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit Ipsen contacts Investors Khalid DEOJEE | + 33 6 66 01 95 26 | Media Sally BAIN | + 1 857 320 0517 | Anne LIONTAS | + 33 7 67 34 72 96 | Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment Ipsen - Initiation of the share repurchase program - 2 June 2025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data